Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease

Area of Science:

• Pharmacology
• Pulmonology
• Rheumatology

Background:

• Nintedanib is an oral triple kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF).
• Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a progressive condition with limited treatment options.
• Targeting pro-fibrotic pathways is a key strategy in managing fibrotic lung diseases.

Purpose of the Study:

• To review the development and approval of nintedanib for SSc-ILD.
• To summarize the mechanism of action, efficacy, and safety of nintedanib in SSc-ILD patients.
• To discuss future perspectives for nintedanib in treating SSc-ILD.

Main Methods:

• Phase III, placebo-controlled, randomized clinical trial data in SSc-ILD patients.
• Analysis of efficacy, focusing on the annual rate of decline in forced vital capacity (FVC).
• Evaluation of safety profiles, including common and serious adverse events.

Main Results:

• Nintedanib significantly reduced the annual rate of FVC decline over 52 weeks compared to placebo in SSc-ILD patients.
• The safety profile was consistent with that observed in IPF patients, with gastrointestinal disorders being the most frequent adverse events.
• Serious adverse events were infrequent and primarily related to the worsening of SSc-related cardiopulmonary involvement.

Conclusions:

• Nintedanib is an approved treatment for SSc-ILD based on robust clinical trial evidence.
• The drug demonstrates a favorable efficacy and safety profile for managing SSc-ILD.
• Nintedanib represents a significant advancement in the therapeutic landscape for SSc-ILD.